Recent improvement in cancer outcomes can largely be linked to the development of targeted therapies. An improved understanding of tumor heterogeneity and molecular pathogenesis has led to the development of therapies that block the growth and spread of cancer by interfering with specific molecules involved in tumor growth and progression. Targeted therapies allow physicians to tailor cancer treatment to the unique set of molecular targets produced by the patient’s tumor. Since targeted therapies are more selective for cancer cells than normal cells, they also result in reduced side effects and improved quality of life compared to conventional cytotoxic therapies.
The emerging field of glycobiology offers a very attractive set of cancer-specific targets found repeatedly on many solid tumors. These tumor associated glycan alterations are seen on the surface of the cancer cell and thus are amenable to antibody therapeutics. Cancer-associated glycan alterations play important functional roles in tumor migration, cell adhesion, and metastasis; therefore, therapeutic antibodies have the potential to not only kill cancer cells but also distort critical biological functions in cancer progression.
Historically, it has been challenging to generate highly specific, high affinity therapeutic antibodies targeting TACAs. Based on technology invented by the Ajit Varki lab at UCSD and exclusively licensed to Sialix, we have developed a robust antibody development platform designed to develop high-quality anti-TACA antibodies – SiaMabsTM – in a rapid and efficient manner.
Padler-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, Muthana S, Chokhawala HA, Cao H, Secrest P, Friedmann-Morvinski D, Singer O, Ghaderi D, Verma IM, Liu YT, Messer K, Chen X, Varki A, Schwab R. Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res. 2011 May 1;71(9):3352-63. Epub 2011 Apr 19.